2024 Partners
Abzena
Lead Partner
Abzena is a bioconjugate and biologics-focused CDMO that pushes development of novel treatments forward at every stage from discovery through commercial launch. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their investments in human health. The company has research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK.
Montgomery Holdings
Program Partner
Veranova
Exhibition Partner
Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients for pharma and biotech customers. Veranova’s global team of highly skilled process chemists and analytical scientists possess over a decade of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody-drug conjugates and polymer drug conjugates.
Vector Laboratories
Exhibition Partner
Vector Laboratories is a trusted critical component manufacturer, working with biopharma companies to employ BioDesign™, a consultation service consolidating chemical synthesis mastery, bioconjugation expertise, and a deep knowledge of how linkers impact ADC performance. Combining the long-established credibility of Vector Laboratories with new proprietary capabilities and technologies gained through the acquisition of Quanta BioDesign, our collaborative approach and dPEG® linker platform provide allow the ultimate flexibility in ADC conjugation, supplying both off-the-shelf and custom linker options.
MilliporeSigma
Exhibition Partner
MilliporeSigma is a leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. Our integrated Millipore® CTDMO Services combine our expertise in contract development, manufacturing, and testing from pre-clinical to commercial to accelerate your milestones and breakthroughs – with one experienced partner. We offer 15+ years of leading expertise in the conjugation of drug linkers to monoclonal antibodies (mAbs) and facilities specialized for handling highly potent compounds. With our recent capacity expansion for single nanogram OEL HPAPI manufacturing and an innovative linker-payload technology portfolio, we are the CDMO partner that ADC customers can trust to take them throughout the drug development journey and to serve their future needs.
www.sigmaaldrich.com/services/contract-manufacturing/adc-bioconjugation
Ajinomoto Bio-Pharma
Brand Partner
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, AJIPHASE® oligonucleotide synthesis, ADC, HPAPI, biocatalysis, continuous flow manufacturing and more.
Asymbio
Exhibition Partner
AsymBio is the emerging business unit of Asymchem Group striving to become a technology-driven, fully-empowered one-stop CDMO services platform for biologic (mAb, ADC, plamsid&mRNA), offering customized services with outstanding quality and efficient performance. We have built an integrated and comprehensive CDMO service platform for ADC drugs (payload-linker, mAb, conjugation), which including but not limited to development, manufacturing, quality control and regulatory affairs. Our one-stop ADC CDMO service platform is able to efficiently empower ADCs
